RGD Reference Report - AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization.

Authors: Mori, Keisuke  Gehlbach, Peter  Yamamoto, Satoru  Duh, Elia  Zack, Donald J  Li, Quihong  Berns, Kenneth I  Raisler, Brian J  Hauswirth, William W  Campochiaro, Peter A 
Citation: Mori K, etal., Invest Ophthalmol Vis Sci. 2002 Jun;43(6):1994-2000.
RGD ID: 28867245
Pubmed: PMID:12037010   (View Abstract at PubMed)


PURPOSE: Adeno-associated viral (AAV) vectors have been used to express several different proteins in the eye. The purpose of this study was to determine whether AAV-mediated intraocular gene transfer of pigment epithelium-derived factor (PEDF) inhibits the development of choroidal neovascularization (CNV) in a murine model.
METHODS: C57BL/6 mice were given intravitreous or subretinal injections of a PEDF expression construct packaged in an AAV vector (AAV-chicken beta-actin promoter-exon 1-intron 1[CBA]-PEDF) or control vector (AAV-CBA-green fluorescent protein[GFP]). After 4 or 6 weeks, the Bruch's membrane was ruptured by laser photocoagulation at three sites in each eye. After 14 days, the area of CNV at each rupture site was measured by image analysis. Intraocular levels of PEDF were measured by enzyme-linked immunosorbent assay.
RESULTS: Four to six weeks after intraocular injection of AAV-CBA-PEDF, levels of PEDF in whole-eye homogenates were 6 to 70 ng. The average area of CNV at sites of the Bruch's membrane rupture showed no significant difference in eyes injected with AAV-CBA-PEDF compared with uninjected eyes. In contrast, 4 to 6 weeks after intraocular injection of 1.5 x 10(9) or 2.0 x 10(10) particles of AAV-CBA-PEDF, the area of CNV at the Bruch's membrane rupture sites had significantly decreased compared with CNV area at rupture sites in eyes injected with AAV-CBA-GFP.
CONCLUSIONS: These data suggest that intraocular expression of PEDF or other antiangiogenic proteins with AAV vectors may provide a new treatment approach for ocular neovascularization.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
Choroidal Neovascularization treatmentIMP 28867245human gene in a mouse modelRGD 
Choroidal Neovascularization treatmentISOSERPINF1 (Homo sapiens)28867245; 28867245human gene in a mouse modelRGD 

Objects Annotated

Genes (Rattus norvegicus)
Serpinf1  (serpin family F member 1)

Genes (Mus musculus)
Serpinf1  (serine (or cysteine) peptidase inhibitor, clade F, member 1)

Genes (Homo sapiens)
SERPINF1  (serpin family F member 1)


Additional Information